false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Congenital Adrenal Hyperplasia, What’s NEW?
Congenital Adrenal Hyperplasia, What’s NEW?
Congenital Adrenal Hyperplasia, What’s NEW?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In the first video summary, Deborah Merck discusses novel therapies for Congenital Adrenal Hyperplasia (CAH), focusing on hormone imbalances and the goal of replacing deficient cortisol and aldosterone. She explores various treatment approaches such as adrenal steroidogenesis inhibitors, glucocorticoid formulations, and gene-based therapies. Additionally, she mentions ongoing studies and clinical trials in this field. No specific credits are mentioned for this video.<br /><br />The second video summary features Philippe Touraine discussing fertility and reproductive issues in CAH patients. He explains the impact of excessive androgen and progesterone production on reproductive disorders and highlights a low fertility rate in CAH women, particularly those with salt-wasting forms. However, he clarifies that with proper hormonal control, CAH women can achieve normal pregnancy rates. Philippe mentions factors influencing fertility, such as insufficient glucocorticoid replacement, genital malformation, high progesterone levels, and psychosocial factors. He also touches on the development of adrenal rest tumors and their impact on fertility. No specific credits are given for this video either.<br /><br />The third video summary explores CYP21A2 deficiency, also known as 21-hydroxylase deficiency, which is an autosomal recessive disease. It discusses the incidence, carrier frequency, and phenotype of the disease, stating that carriers usually have no symptoms or mild androgen excess. The video mentions variations in symptoms and hormone levels among carriers and highlights potential advantages, such as a more pronounced cortisol response to stress and lower mortality due to infections. It also discusses lower rates of psychiatric diagnoses among carriers after the birth or diagnosis of a child with CAH. The video concludes by suggesting that more research is needed to fully understand the biological and physiological advantages of being a carrier of CYP21A2 mutations. No specific credits are mentioned for this video either.
Keywords
novel therapies
Congenital Adrenal Hyperplasia
hormone imbalances
deficient cortisol
aldosterone
adrenal steroidogenesis inhibitors
glucocorticoid formulations
gene-based therapies
fertility
reproductive disorders
low fertility rate
CYP21A2 deficiency
autosomal recessive disease
×